ClinicalTrials.gg
RecruitingNCT07125365UKIAb RegistryUpdated Aug 15, 2025

UK Islet Autoantibody Registry

An observational study in Type 1 Diabetes (T1D), Registry and Pre-diabetes, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 6 Months to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by University of Oxford · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
6 Months to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 41 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.

Planned enrollment
19th of 54
350 · median 133
Started
2025
with 11 others
Observational
54 of 268
14 open now
Primary completion
2027-05
later than 24 of 40 live
Registered
255th of 268
by date
Lead sponsor
7 of 268
University of Oxford

Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 54 observational ones that give a count, is one of 12 that started in 2025, is one of 54 observational ones, reaches primary completion later than 24 of the 40 other live ones, and was the 255th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Months to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, or all of them as a file.
02

Study summary

Type 1 diabetes (T1D) is a life-long condition where the immune system destroys part of the body (the pancreas) which makes the chemical, insulin. Insulin is needed to control blood sugar levels. Treatment involves life-long insulin replacement by injection or insulin pump.

Previous research has shown that the development of T1D occurs through different stages. This starts with a phase where there are no symptoms, which can last months or years, before symptoms of T1D develop and a person becomes unwell. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies. The risk of developing T1D increases with presence of markers in the blood called islet autoantibodies (IAb). Children with two or more IAb have an 80-90% chance of developing T1D within 15 years. It is almost certain that they will develop the condition in their lifetime. Children with only one IAb have a much lower risk of developing T1D (around 15%). Less is understood about the natural history of being IAb positive in adults, and the investigators hope this study will help them understand more.

The aim of the research is to understand what it is like to live with being at risk of T1D, what information and support people need, and whether they use NHS services more than others, for example due to being anxious about developing T1D. The investigators will work with the public and patient involvement group using information from the research and, with the charity Diabetes UK, to create a policy statement about the type of care that is needed to support these individuals.

To be able to do this research, tbhe investigators need first to recruit these rare individuals into one single registry of children, young people and adults who have islet autoantibodies in their blood. This will also allow the invetigators to collect data from individuals in the registry to compare this to data from other countries, to help understand why people progress from being islet autoantibody positive to requiring insulin in the UK.

People entering the registry will also be told if a drug is licensed in the UK to help delay T1D onset. Participants can also consent to be contacted about any research studies, which are testing drugs or interventions to prevent or delay the start of T1D.

Read the detailed description

BACKGROUND AND RATIONALE Type 1 diabetes can be identified in the pre-clinical phase Understanding of the natural history of Type 1 diabetes (T1D) has made it possible to diagnose children, young people and adults (CYPA) in the preclinical phase. The presence of ≥ 2 Islet autoantibodies (IAb) in serum, to 4 different proteins (insulin, Glutamic Acid Decarboxylase (GADA), insulinoma-2-associated autoantibodies (IA-2A), and/or zinc transporter 8 autoantibodies (ZnT8A) identifies individuals who will develop T1D. The latency period before clinical diagnosis can last months or years, with individuals with ≥2 IAb moving between stage 1 (normoglycaemia), stage 2 (dysglycaemia) to stage 3 (hyperglycaemia), or clinical disease.

Data from combined longitudinal cohorts shows that ≥ 2 IAb in children predicts that stage 3 T1D will develop in over 80% over the next 15 years, and near 100% over a lifetime, whereas only around 10-15% children with a single IAb progress to insulin requirement. Individuals may therefore live for many years with the knowledge they may develop T1D .

Potential benefits of early identification of T1D Identifying T1D before symptoms develop has several potential advantages, including reducing presentation with life-threatening diabetic ketoacidosis (DKA) and its associated morbidity, and potentially reducing the psychological trauma at diagnosis which some families liken to 'post-traumatic distress' . Reducing DKA and hospitalisations can also reduce associated health care costs. Screening identifies individuals suitable for trials to prevent or delay T1D. Therapies are now being trialled in stage 2 T1D, for example, the ATG prevention trial 'STOP-T1D'.

Concerns about screening Informing someone that they have positive IAb may cause psychological stress. For example, the Fr1da study, which has now tested > 170,000 children for IAb, found that informing parents of their child's positive IAb result induced stress (assessed by the Patient Health Questionnaire-9); this stress declined after 12 months of follow up. Within the registry, the investigators have recourse to the advice of a senior clinical psychologist, who can provide signposting support for individuals identified through the registry, if psychological concerns arise.

Screening initiatives Until recently, screening strategies have focussed on first-degree relatives (FDR) of individuals with T1D, who have a 15 times higher risk of developing stage 3 T1D compared to the general population. However, since > 85% of people with T1D do not have a family history, general population screening efforts have been started.

There are now several different screening programs in the UK identifying children, young people and adults with IAbs. It is anticipated that there are approximately 700 such children and adults from the different research platforms. These individuals do not typically present to their general practitioner as they have no symptoms, and therefore it is extremely rare to know of such individuals in the UK. Individuals can also be identified from clinical care (personal communication Besser \& Randell, BSPED). In order to answer our research questions, the investigators need a mechanism to identify, recruit and consent such individuals into a single combined registry.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Registry
  • Pre-diabetes
  • Screening
04

Who can participate

Ages eligible
6 Months to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential participants will be identified via:

  • Established research platforms e.g. BOX, INNODIA, ADDRESS-2, PoINT, SINTIA, TrialNet, ELSA, T1DRA, (this is not an exhaustive list)
  • Referral from clinical care
  • Self-referral

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 6 months - 70 years
  • IAb positive (≥ 1) to any of the following: insulin/GAD/IA2/ZnT8, confirmed in a reference laboratory.
  • Participant is willing and able to give for participation in the study (≥ 16 years old), or for \< 16 years, parental/guardian consent (plus assent, where appropriate)
  • Living in the UK
  • For ADDRESS-2 participants only: have taken part in a blood draw as part of ADDRESS-2
  • For the qualitative interviews: Have been living with (or is a parent/guardian of a child who has been living with) a positive IAb result for ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • Ongoing subcutaneous insulin requirement
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • UKIAb

    Children and adults aged 6 months - 70 years, positive for ≥ 1 islet autoantibody (IAb)

06

What researchers measure

Primary outcomes

  1. Number of individuals enrolled on the registry

    Time frame: 36 months

Secondary outcomes

  1. Participants' perspectives and experiences

    Interviews, to to understand the lived experience of being IAb positive or having a child who is IAb positive.

    Time frame: 28 months

  2. Participants' perspectives and experiences

    Interviews, to understand people's information and support needs when living with an IAb result, to improve the information and support given to people and their families who receive a positive T1D IAb result in the future and create a position statement informed by our findings.

    Time frame: 28 months

  3. Frequency and risk factors (e.g. antibody profile, age) associated with clinical outcomes incident diabetes as defined by start of insulin use and number of DKA episodes

    We will undertake data linkage with routinely collected NHS clinical datasets held by NHSE (and the equivalent for the devolved nations)

    Time frame: 28 months

  4. Frequency and risk factors (e.g. antibody profile, age) associated with HbA1c mmol/l

    To undertake data linkage with routinely collected NHS clinical datasets held by NHSE (and the equivalent for the devolved nations)

    Time frame: 28 months

  5. Frequency of attendance in primary care

    To assess the status of being IAb positive on health service usage and clinical outcomes using comparator cohorts (e.g. CPRD/HES)

    Time frame: 36 months

  6. Frequency of attendance and inpatient admission to secondary/ tertiary care

    To assess the status of being IAb positive on health service usage and clinical outcomes using comparator cohorts (e.g. CPRD/HES)

    Time frame: 36 months

  7. IAb type (IA, IA-2, ZnT8, GAD, ICA)

    To compare IAb characteristics to similar cohorts from international registries

    Time frame: 36 months

  8. IAb laboratory (location)

    To compare IAb characteristics to similar cohorts from international registries

    Time frame: 36 months

  9. IAb titre (mULN)

    To compare IAb characteristics to similar cohorts from international registries

    Time frame: 36 months

  10. Demographic data

    To compare demographic characteristics to similar cohorts from international registries

    Time frame: 36 months

  11. Time to clinical diagnosis (defined as stage 3 T1D) according to standard diagnostic criteria

    To assess risk of progression to stage 3 T1D in IAb positive individuals in the UK

    Time frame: 36 months

  12. Number of individuals who have consented and enrolled to the registry

    To assess consent to the registry vs enrolment

    Time frame: 36 months

  13. IAb number (1-4)

    To compare the proportion identified as confirmed positive from clinical care vs reference laboratories

    Time frame: 36 months

  14. IAb type (IA-2, IA, ZnT8, GAD, ICA)

    To compare the proportion identified as confirmed positive from clinical care vs reference laboratories

    Time frame: 36 months

  15. IAb titre (mULM)

    To compare the proportion identified as confirmed positive from clinical care vs reference laboratories

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — All IPD will be considered for data sharing.

Supporting information: Study protocol, Informed consent form

Time frame: Access to data will not be considered until after the primary publication for the registry has been published

Access criteria: Subject to participant consent, data will be shared with other researchers for research projects that have appropriate ethical approval. Requests for access to the data will be controlled by the Data Access Committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 22 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Aug 15, 2025
StartActual
Jul 11, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07125365
Collaborators
Cardiff University, University of Edinburgh, University of Cambridge, University of Dundee, University of Birmingham, Imperial College London, University of Bristol, King's College London, Oxford University Hospitals NHS Trust, University of Exeter
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Jul 11, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Aug 15, 2025

Study contacts

UKIAb Registry Manager
Contact
ukiab@ndm.ox.ac.uk
+44(0)7765 932065
Rachel Besser
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion